• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Pharvaris N.V. (NQ: PHVS )

    20.35 -0.20 (-0.97%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Pharvaris N.V.

    < Previous 1 2 3 4 5 Next >
    Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
    From Pharvaris N.V.
    Via GlobeNewswire
    Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference
    From Pharvaris N.V.
    Via GlobeNewswire
    Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting
    Data from randomized clinical studies and long-term extension studies support deucrictibant’s potential best-in-class profile, detailing its injectable-like efficacy, placebo-like tolerability, and... 
    From Pharvaris N.V.
    Via GlobeNewswire
    Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings
    From Pharvaris N.V.
    Via GlobeNewswire
    Pharvaris to Host Virtual Investor Event on October 23, 2024
    From Pharvaris N.V.
    Via GlobeNewswire
    Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop
    From Pharvaris N.V.
    Via GlobeNewswire
    Pharvaris Provides Business Update and Expands Development Program for Deucrictibant
    From Pharvaris N.V.
    Via GlobeNewswire
    Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024
    From Pharvaris N.V.
    Via GlobeNewswire
    Pharvaris Presents Data at the Bradykinin Symposium 2024
    From Pharvaris N.V.
    Via GlobeNewswire
    Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium
    From Pharvaris N.V.
    Via GlobeNewswire
    PHVS Stock Earnings: Pharvaris Beats EPS for Q2 2024
    PHVS stock results show that Pharvaris beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update
    From Pharvaris N.V.
    Via GlobeNewswire
    Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense
    Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine. 
    Via Investor's Business Daily
    Pharvaris Announces Annual Meeting of Shareholders
    From Pharvaris N.V.
    Via GlobeNewswire
    Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses
    From Pharvaris N.V.
    Via GlobeNewswire
    Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses
    From Pharvaris N.V.
    Via GlobeNewswire
    PHVS Stock Earnings: Pharvaris Misses EPS for Q1 2024
    PHVS stock results show that Pharvaris missed analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
    From Pharvaris N.V.
    Via GlobeNewswire
    PHVS Stock Earnings: Pharvaris Misses EPS for Q4 2023
    PHVS stock results show that Pharvaris missed analyst estimates for earnings per share the fourth quarter of 2023. 
    Via InvestorPlace
    Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    From Pharvaris N.V.
    Via GlobeNewswire
    Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
    From Pharvaris N.V.
    Via GlobeNewswire
    Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
    From Pharvaris N.V.
    Via GlobeNewswire
    Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
    From Pharvaris N.V.
    Via GlobeNewswire
    Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
    From Pharvaris N.V.
    Via GlobeNewswire
    Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
    From Pharvaris N.V.
    Via GlobeNewswire
    Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
    Antagonism of the bradykinin B2 receptor via treatment with deucrictibant resulted in statistically significant reduction in rate of HAE attacks 
    From Pharvaris N.V.
    Via GlobeNewswire
    Pharvaris Announces Extraordinary Meeting of Shareholders
    From Pharvaris N.V.
    Via GlobeNewswire
    Pharvaris to Present at the WSAAI Annual Meeting 2024
    From Pharvaris N.V.
    Via GlobeNewswire
    Top-Notch Pharvaris Eyes Profit-Taking Zone On A Key FDA Decision
    The company is working on a treatment for swelling attacks associated with a genetic disease. 
    Via Investor's Business Daily
    Exposures Product Safety
    FDA Clears Pharvaris' Trial For Investigational Drug For Swollen Blood Vessels, Stock Jumps
    Pharvaris receives FDA approval to advance deucrictibant for hereditary angioedema prophylaxis, lifting clinical hold. Learn about the latest developments in HAE treatment. 
    Via Benzinga
    Exposures Product Safety
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.